| Description | C16G2 TFA is a specific targeted antimicrobial peptide (STAMP) that targets the cariogenic oral pathogen Streptococcus mutans. C16G2 TFA specifically recognizes and disrupts the bacterial cell membrane, causing small molecule leakage and loss of membrane potential, leading to bacterial killing. C16G2 TFA is a specific targeted antimicrobial peptide (STAMP) that targets the cariogenic oral pathogen Streptococcus mutans. C16G2 TFA specifically recognizes and disrupts the bacterial cell membrane, causing small molecule leakage and loss of membrane potential, leading to bacterial killing. C16G2 TFA exhibits higher selectivity and efficacy against Streptococcus mutans, unlike broad-spectrum antimicrobial peptides[1]... Read More | CGGRGD TFA, a RGD derivative with cysteine as its N-terminal[1] | Epitalon TFA is an anti-aging agent and a telomerase activator. Epitalon TFA has an inhibitory effect of the on the development of spontaneous tumors in mice, has geroprotective actions and intranasal administration increases neuronal activity. Epitalon TFA can be used for cancer, old age and Epitalon TFA is an anti-aging agent and a telomerase activator. Epitalon TFA has an inhibitory effect of the on the development of spontaneous tumors in mice, has geroprotective actions and intranasal administration increases neuronal activity. Epitalon TFA can be used for cancer, old age and Retinitis Pigmentosa[1]... Read More | Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF)[1][2][3] | PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor agonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively[1] |